Golimumab is often a human monoclonal antibody administered when per month by subcutaneous injection. Although it has a similar basic safety and efficacy profile to other TNFi, golimumab is much less successful than other TNFi in individuals who have unsuccessful several biological treatments. The latest therapeutic approach to RA permitted https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/